Polycystic ovary syndrome, better known as PCOS, is finally getting a rebrand. The condition has now been renamed polyendocrine metabolic ovarian syndrome, or PMOS—a far more accurate descriptor, in a move aimed at reducing confusion and stigma around the condition.
According to the World Health Organization, PMOS affects roughly one in eight women globally—around 170 million people—yet an estimated 70 per cent remain undiagnosed. The rechristening hopes to better reflect the complex nature of the condition. Many patients diagnosed with PCOS don’t actually have cysts on their ovaries but often experience broader hormonal and metabolic symptoms.
The change was announced on May 12 in the British medical journal, The Lancet. Under the latest criteria, PMOS is diagnosed if someone meets two out of three markers: (1) excess male hormones called androgens, (2) irregular menstrual cycles, and (3) high levels of anti-mullerian hormone (AMH) in blood, or ovaries with multiple arrested follicles visible on ultrasound.
In other words: this isn’t just about periods or ovaries. The new name reframes the condition as a full-body endocrine and metabolic disorder. Alongside menstrual and fertility issues, PMOS can cause acne, excess facial hair, hair thinning and skin changes, and is linked to a higher risk of obesity, Type 2 diabetes, cardiovascular disease and sleep apnea.
Doctors and researchers hope the new name will do more than tidy up medical terminology as funding for studying the disorder and treatments will no longer be limited to sources that focus on ovarian and reproductive health, potentially leading to earlier diagnoses and more comprehensive care.
The transition from PCOS to PMOS is expected to roll out gradually over the next three years, with the term expected to officially replace PCOS into the International Classification of Diseases in 2028.
